Although they found no mutations in TET2, they identified promoter methylation of TET2 in 5 of 35 low-grade gliomas, whereas low-grade gliomas with IDH1/2 mutations showed no hypermethylation of the TET2 promoter. The gene discussed is TET2; the disease is central nervous system cancer.